Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs)

Atavistik Bio完成1.2亿美元B轮融资，用于推进治疗遗传性出血性毛细血管扩张症（HHT）和骨髓增殖性肿瘤（MPNs）的选择性变构小分子疗法的开发。

• Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms (MPNs) through clinical proof of concept

• 所得款项将用于支持Atavistik Bio口服变构AKT1选择性抑制剂在遗传性出血性毛细血管扩张症（HHT）中的进展，以及用于骨髓增生性肿瘤（MPNs）的JAK2 V617F突变选择性抑制剂项目通过临床概念验证。

• Atavistik Bio anticipates initiating its clinical trial in HHT in the first half of 2026

• Atavistik Bio预计将在2026年上半年启动其在HHT的临床试验。

CAMBRIDGE, Mass., December 18, 2025-- Atavistik Bio, a biotechnology company discovering the next generation of precision allosteric therapeutics, today announced that it has raised a $120 million Series B financing to support the advancement of selective allosteric small molecule therapeutics for the treatment of HHT and MPNs.

马萨诸塞州剑桥市，2025年12月18日——Atavistik Bio是一家致力于发现下一代精准变构治疗药物的生物技术公司，该公司今天宣布已完成1.2亿美元的B轮融资，以推进用于治疗遗传性出血性毛细血管扩张症（HHT）和骨髓增殖性肿瘤（MPNs）的选择性变构小分子治疗药物的研发。

The financing was led by Nextech Invest and The Column Group, with participation from existing investor Lux Capital and new investor Regeneron Ventures. Atavistik Bio will use the proceeds from the Series B financing to advance its oral allosteric AKT1-selective inhibitor for HHT and its JAK2 V617F mutant-selective inhibitor program for MPNs through clinical proof of concept..

本轮融资由Nextech Invest和The Column Group领投，现有投资者Lux Capital和新投资者Regeneron Ventures参投。Atavistik Bio将利用B轮融资所得资金，推进其用于治疗HHT的口服变构AKT1选择性抑制剂，以及用于MPNs的JAK2 V617F突变选择性抑制剂项目，直至临床概念验证阶段。

“We’re thrilled to announce our Series B financing, and grateful for the support of both our existing and new investors. With this capital, we are well-positioned to advance both our HHT and MPN programs through key clinical proof-of-concept milestones, with the HHT program expected to enter the clinic in the first half of 2026,” said Bryan Stuart, Chief Executive Officer at Atavistik Bio.

“我们很高兴地宣布我们的B轮融资，并对现有投资者和新投资者的支持表示感谢。通过这笔资金，我们有能力将我们的HHT和MPN项目推进到关键的临床概念验证阶段，其中HHT项目预计将在2026年上半年进入临床试验，”Atavistik Bio首席执行官Bryan Stuart表示。

“Our precision allostery approach holds tremendous potential to deliver best-in-class therapeutics with superior efficacy and tolerability profiles. Our team is working with tremendous passion and momentum to translate that promise into meaningful outcomes for patients.”.

“我们的精确变构方法有巨大潜力提供具有优越疗效和耐受性的最佳治疗药物。我们的团队正以极大的热情和动力将这一承诺转化为对患者有意义的成果。”

HHT is a severe bleeding disorder that affects more than 1.6 million people globally, with no approved therapies currently available. This condition often leads to frequent bleeding episodes, resulting in chronic anemia, organ damage, and a reduced lifespan. AKT1 hyperactivation is a hallmark of HHT and has been shown to drive the vascular pathology of HHT.

HHT是一种严重的出血性疾病，影响全球超过160万人，目前尚无获批的治疗方法。该病常导致频繁的出血发作，引发慢性贫血、器官损伤以及寿命缩短。AKT1过度激活是HHT的一个标志性特征，已被证明会驱动HHT的血管病理变化。

Selectively inhibiting AKT1, the primary AKT isoform and driver of abnormal endothelial growth implicated in HHT, offers a novel and potentially disease-modifying therapeutic approach for this difficult disease. Although there has been substantial investment in pan-AKT inhibitors, their use is limited by AKT2-driven toxicities, most notably hyperglycemia, which impact tolerability and restrict their use for chronic dosing.

选择性抑制AKT1——主要的AKT异构体以及与HHT相关的异常内皮生长的驱动因素——为这一棘手疾病提供了新颖且潜在改变病程的治疗策略。尽管在泛AKT抑制剂方面已有大量投资，但其使用受到AKT2驱动的毒性限制，尤其是高血糖，这影响了耐受性并限制了其在长期给药中的应用。

Atavistik Bio has developed an oral allosteric inhibitor that selectively inhibits AKT1, overcoming the shortcomings of pan-AKT inhibitors and offering improved therapeutic potential and tolerability..

Atavistik Bio 开发了一种口服变构抑制剂，可选择性抑制 AKT1，克服了泛 AKT 抑制剂的缺点，提供了更高的治疗潜力和耐受性。

MPNs are a group of rare chronic blood cancers for which current treatment options are limited. The JAK2 V617F mutation is the most common driver mutation in patients living with MPNs, affecting approximately 95% of patients with polycythemia vera, 60% of patients with essential thrombocythemia, and 55% of patients with myelofibrosis.

骨髓增殖性肿瘤（MPNs）是一组罕见的慢性血液癌症，目前的治疗选择有限。JAK2 V617F突变是MPN患者中最常见的驱动突变，约95%的真性红细胞增多症患者、60%的原发性血小板增多症患者和55%的骨髓纤维化患者受其影响。

Approved pan-JAK inhibitors, such as ruxolitinib, provide symptom relief, but non-selectively inhibit both mutant and wild-type JAK2. This limits the ability to reduce JAK2 V617F mutant allele burden and can disrupt normal blood cell production regulated by wild-type JAK2, contributing to adverse events and treatment discontinuation.

批准的泛JAK抑制剂（如鲁索替尼）可缓解症状，但会非选择性地抑制突变型和野生型JAK2。这限制了减少JAK2 V617F突变等位基因负荷的能力，并可能扰乱由野生型JAK2调控的正常血细胞生成，导致不良事件和治疗中断。

Selectively targeting the JAK2 V617F mutation has the potential to reduce mutant allele burden, preserve normal bone marrow function, and have a disease modifying impact that will substantially improve long term outcomes for patients with MPNs..

选择性靶向JAK2 V617F突变有潜力减少突变等位基因负荷，保留正常骨髓功能，并对疾病产生修饰作用，从而显著改善MPN患者的长期预后。

“We’ve been continually impressed by the exceptional quality of the compounds discovered from Atavistik Bio’s proprietary AMPS™ platform and by the team’s ability to consistently execute against critical milestones,” said John A. Josey, PhD, Atavistik Board Chair. “Atavistik Bio’s HHT and MPN programs would represent enormous advancements in the treatment of these respective diseases.

“我们一直对Atavistik Bio专有的AMPS™平台发现的化合物的卓越质量以及团队持续实现关键里程碑的能力印象深刻，”Atavistik董事会主席John A. Josey博士说道。“Atavistik Bio的HHT和MPN项目将代表这些疾病治疗方面的巨大进步。”

We look forward to seeing Atavistik Bio move these programs into the clinic and bring them closer to patients in need.”.

我们期待看到Atavistik Bio将这些项目推进到临床，并使其更接近有需要的患者。”

About Atavistik Bio

关于Atavistik Bio

Atavistik Bio is a clinical stage biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs. Since its inception, Atavistik Bio has rapidly established an emerging pipeline of allosteric therapeutics with the potential to achieve superior efficacy and tolerability profiles by leveraging the power of allostery..

Atavistik Bio是一家临床阶段的生物技术公司，致力于加速发现和开发变革性的精准变构疗法，以满足严重的未满足患者需求。自成立以来，Atavistik Bio通过利用变构的力量，迅速建立了一个新兴的变构治疗管线，具有实现更优疗效和耐受性潜力。

Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, Nextech Invest, Lux Capital, and Regeneron Ventures. To learn more, visit us at atavistikbio.com and follow us on LinkedIn..

Atavistik Bio 由一支经验丰富的药物研发团队领导，该团队有着成功开发已上市小分子疗法的可靠记录，并受到顶级投资机构的支持，包括 The Column Group、Nextech Invest、Lux Capital 和 Regeneron Ventures。欲了解更多信息，请访问 atavistikbio.com 并在 LinkedIn 上关注我们。

Contact:

联系人：

Media Contact:

媒体联系人：

Liz Melone

莉兹·梅隆

Melone Communications, LLC

梅洛内通信有限责任公司

liz@melonecomm.com

liz@melonecomm.com